Juno Therapeutics, Inc. (JUNO) Stake Held by Fairfield Bush & CO.

Fairfield Bush & CO. continued to hold its stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,475 shares of the biopharmaceutical company’s stock at the close of the second quarter. Fairfield Bush & CO.’s holdings in Juno Therapeutics were worth $642,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of the stock. Utah Retirement Systems grew its holdings in Juno Therapeutics by 1.8% during the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock valued at $347,000 after purchasing an additional 200 shares during the last quarter. State of Wisconsin Investment Board grew its holdings in Juno Therapeutics by 1.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 210 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the last quarter. Amalgamated Bank grew its holdings in Juno Therapeutics by 19.0% during the 2nd quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 1,741 shares during the last quarter. Finally, Evercore Wealth Management LLC grew its holdings in Juno Therapeutics by 6.7% during the 2nd quarter. Evercore Wealth Management LLC now owns 32,062 shares of the biopharmaceutical company’s stock valued at $958,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors own 67.38% of the company’s stock.

Several brokerages recently commented on JUNO. Vetr downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.47 price target on the stock. in a report on Monday, August 7th. Wells Fargo & Company reiterated an “outperform” rating and set a $54.00 price target (up from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Maxim Group reiterated a “buy” rating and set a $56.00 price target (up from $34.00) on shares of Juno Therapeutics in a report on Monday. Zacks Investment Research upgraded shares of Juno Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 20th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. Juno Therapeutics currently has an average rating of “Hold” and an average target price of $37.83.

WARNING: “Juno Therapeutics, Inc. (JUNO) Stake Held by Fairfield Bush & CO.” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/10/10/juno-therapeutics-inc-juno-stake-held-by-fairfield-bush-co.html.

Shares of Juno Therapeutics, Inc. (JUNO) traded down 2.13% during trading on Tuesday, reaching $42.75. 679,426 shares of the company’s stock were exchanged. The company has a 50 day moving average of $41.12 and a 200 day moving average of $29.70. The stock’s market cap is $4.48 billion. Juno Therapeutics, Inc. has a 12-month low of $17.52 and a 12-month high of $47.03.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The company had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same quarter in the prior year, the business earned ($0.64) earnings per share. Juno Therapeutics’s revenue was down 22.8% on a year-over-year basis. Equities research analysts anticipate that Juno Therapeutics, Inc. will post ($3.12) EPS for the current year.

In other Juno Therapeutics news, major shareholder Douglas K. Bratton sold 8,000,000 shares of Juno Therapeutics stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $27.00, for a total transaction of $216,000,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Bernard J. Cassidy sold 28,000 shares of Juno Therapeutics stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the sale, the general counsel now owns 55,970 shares of the company’s stock, valued at $2,514,172.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,085,004 shares of company stock valued at $219,551,561. Company insiders own 15.26% of the company’s stock.

Juno Therapeutics Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

What are top analysts saying about Juno Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit